Latest News – Page 1192 – Philippine Endourological Society

UncategorizedOctober 19, 2019

SIU 2019: Long-Term Outcomes in Patients with Biochemical Recurrence or PSA Persistence Following Radical Prostatectomy

Athens, Greece (UroToday.com) Dr. Derya Tilki was the first to present at the Educating Masterclass on Biochemical Recurrence after Radical Prostatectomy. Her talk focused on the long-term outcomes of patients with biochemical recurrence (BCR) after radical prostatectomy. Following radical prostatectomy, approximately 27-53% of patients will experience BCR.1 However, only 30% of patients experiencing BCR after primary surgery will […]

UncategorizedOctober 19, 2019

Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer – Beyond the Abstract

Treatment options for non-metastatic castration resistant prostate cancer (nmCRPC) expanded considerably with the completion of SPARTAN, PROSPER and ARAMIS trials. Novel androgen receptor inhibitors have shown improved outcomes for nmCRPC patients at risk for the development of metastases.1-3 In all of these studies, the absence of metastases was assessed by virtue of conventional cross-sectional imaging […]

UncategorizedOctober 19, 2019

SIU 2019: Adjuvant Therapy for High-risk Renal Cell Carcinoma: Current Status

Athens, Greece (UroToday.com) Dr. Ricardo Rendon presented on the adjuvant treatment of high-risk renal cell carcinoma (RCC). The cancer-specific survival (CSS) for localized RCC following surgical resection is 84% at 5 years, and 76% at 10 years. However, for patients with high-risk features, the CSS is around 30-40%. The optimal treatment strategy for high-risk RCC patients […]

UncategorizedOctober 19, 2019

SIU 2019: Management of Renal Cell Carcinoma Caval Thrombus in 2019

Athens, Greece (UroToday.com) Dr. Amlesh Seth gave an overview of the current treatment of renal cell carcinoma (RCC) with caval thrombus. Approximately 2-3% of all adult malignancies are RCC. Inferior vena cava (IVC) thrombus occurs in 4-10% of all RCCs. The thrombus can be localized to the renal vein, but can also reach up to the right […]

UncategorizedOctober 18, 2019

Dose-response Relationships Between Cigarette Smoking and Kidney Cancer: A Systematic Review and Meta-analysis – Beyond the Abstract

In our study, besides providing the most complete and updated quantification of the association between cigarette smoking and kidney cancer risk, for the first time we provided the dose-risk functions for smoking intensity, duration, and time since quitting. Using an innovative approach for the identification of original publications, we conducted the present systematic review. Dose-risk […]

UncategorizedOctober 18, 2019

SIU 2019: Chemotherapy and ARATs vs Metastases-Directed Therapy for mHSPC

Athens, Greece (UroToday.com) Markus Graefen, MD, gave an overview of the role of experimental metastases directed therapies in the era of proven life-prolonging drugs and radiation to the primary tumor in the setting of metastatic hormone-sensitive prostate cancer (mHSPC). Currently, the standard treatment of mHSPC includes androgen deprivation therapy (ADT) and either docetaxel or androgen […]

UncategorizedOctober 18, 2019

SIU 2019: Cytoreductive Nephrectomy — Has it Had Its Day?

Athens, Greece (Urotoday.com) Dr. Alessandro Volpe gave an overview of the current role of cytoreductive nephrectomy in renal cell carcinoma (RCC). Up to one third of patients with RCC will present with metastatic disease. The concept of cytoreductive nephrectomy for metastatic RCC patients received significant recognition with the publication by Dr. Robert Flanigan’s paper in 2001 […]

UncategorizedOctober 18, 2019

Immunological Risk Stratification of Bladder Cancer Based on Peripheral Blood Natural Killer Cell Biomarkers.

Bladder cancer (BC) is highly immunogenic. Bacillus Calmette-Guérin (BCG) immunotherapy offers the best results in non-muscle-invasive BC (NMIBC). Natural killer cells (NKcs) play decisive roles in BCG-mediated immune response and in general cancer immune-surveillance. To analyze killer-cell immunoglobulin-like receptors (KIRs), their human leukocyte antigen class-I (HLA-I) ligands, and the expression of DNAX Accessory Molecule-1 (DNAM-1/CD226) […]

UncategorizedOctober 18, 2019

Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.

Mitomycin C (MMC) is widely used, but the optimal dose and schedule have not been established. To evaluate the ablative power and patient safety of a short-term intensive schedule of intravesical MMC in patients with recurrent non-muscle-invasive bladder cancer (NMIBC). This was a prospective, single-center, nonrandomized study that compared 47 patients (group 1) with a […]

UncategorizedOctober 18, 2019

High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.

Overexpression of aurora kinase A (AURKA) confers a poor prognosis in patients with urothelial carcinoma of the bladder. The prognostic value of high aurora kinase B (AURKB) expression in local bladder cancer is not well defined, and whether the prognostic value of either AURKA or AURKB is affected by the use of chemotherapy is unknown. […]

1
2
3
…
1,189
1,190
1,191
1,192
1,193
1,194
1,195
…
1,440
1,441
1,442